Bayer and the Broad Institute of MIT and Harvard renewed their research alliance, adding 5 years to a 10-year collaboration that yielded three clinical oncology candidates. This research collaboration is aimed at identifying cancer targets and exploring novel therapeutic approaches in oncology.
The research is guided by joint project and governance teams. In addition to identifying investigational drugs for novel oncology targets and generating the associated intellectual property, the organizations will continue to openly share the biological knowledge generated with the scientific community, including through publicly available datasets and publications in academic journals.
As a result of this collaboration, Bayer's mutant EGFR/HER2 inhibitor is currently in Phase I of clinical trials. This is the first reversible small molecule inhibitor targeting EGFR exon 20 insertion mutations and HER2 activating mutations to undergo clinical testing.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!